Anzeige
Meldung des Tages: Lithium ist zurück — und diesmal führen Institutionen den Markt an

Vanda Pharmaceuticals Aktie News

Aktie
WKN:  A0JJT3 ISIN:  US9216591084 US-Symbol:  VNDA Branche:  Biotechnologie Land:  USA
8,01 $
-0,09 $
-1,11%
6,7716 € 23.01.26
Depot/Watchlist
Marktkapitalisierung *
348,72 Mio. €
Streubesitz
14,40%
KGV
-14,97
Index-Zuordnung
-

Vanda Pharmaceuticals News

10.06.25 - PR Newswire
Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S
Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-​Marie-Tooth disease Type 2S PR Newswire
27.05.25 - PR Newswire
Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting
Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting PR Newswire
16.05.25 - PR Newswire
Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025
Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025 PR Newswire
07.05.25 - PR Newswire
Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results
Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results PR Newswire
05.05.25 - PR Newswire
Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026
Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026 PR Newswire
02.05.25 - PR Newswire
Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025
Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025 PR Newswire
23.04.25 - PR Newswire
FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA
FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA PR Newswire
07.04.25 - PR Newswire
Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting
Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting PR Newswire
31.03.25 - PR Newswire
Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia
Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia PR Newswire
24.02.25 - PR Newswire
Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"
Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-​Marie-Tooth disease type 2S" PR Newswire
13.02.25 - PR Newswire
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results PR Newswire
05.02.25 - PR Newswire
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025 PR Newswire
03.02.25 - PR Newswire
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist PR Newswire
27.01.25 - PR Newswire
Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis
Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis PR Newswire

Newssuche

Videos

newspaper
22.01.26 -5,56%
Trading Insights vom 22.01.26
Preisschock bei Erdgas! Was sind die Gründe, wie geht man damit um? Gold auf neuem Allzeithoch: wie ... Mehr »
Anzeige

Aktie im Fokus

GOLD-AUSBRUCH
GMV Minerals
0,187 €
+13,3%
GMV Minerals Chart
Von der PEA zum Milliarden-Potenzial
Mehr zur Aktie »